clinical trial · NCT06435221
Safety Study of Cytisinicline in Adult Combustible and/or E-cigarette Smokers
Achieve Life Sciences·phase3·completed·n = 479
Smoking CessationVaping CessationCytisinicline
brief summary
Safety assessment of long-term 3 mg cytisinicline three times daily (TID) exposure for 52 weeks is the main purpose of this study, conducted in the United States.
started
May 28, 2024
primary completion
Sep 29, 2025
completion
Oct 6, 2025
last updated
Nov 26, 2025
official title
A Multicenter, Open-Label Study Assessing Long-Term Exposure With Cytisinicline 3 mg TID
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol